Ultragenyx Pharmaceutical
Prezzo: 24.35Società e modello di business
Ultragenyx Pharmaceutical is a biotechnology company focused on developing innovative therapies for rare genetic diseases. Its core products include enzyme replacement therapies and gene therapies targeting specific conditions. Major business segments encompass research and development, with primary revenue sources derived from product sales and collaborations with other pharmaceutical firms.
Profilo di investimento
The investment profile of Ultragenyx Pharmaceutical is more aligned with growth investors due to its focus on developing new therapies and potential for future revenue generation. However, the high risk associated with its financial performance and volatility may deter conservative investors.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -6.11 Rischio
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -34.3% ↓
- Sorpresa EPS
- -23.7% peggio del previsto
- Volatilità 20g
- 3.5% stabile
Dati FMP / FinFeed aggiornati:
2026-06-10
Racc.: Vendi
Potenziale: 28
Rischio: 75
Aggiornato: 2026-06-13 02:45
Come funziona la raccomandazione
Perché l'AI la pensa così:
Weak fundamentals and negative momentum raise significant concerns.
Traccia in portafoglio
Grafico prezzo
Raccomandazione AI
Previsione analista
Evento calendario
Segnale positivo
Segnale negativo
Neutrale / aggiornamento
Mantieni / informativo
B My buy
S My sell
Cambiamenti di raccomandazione AI
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-05-16 02:38 | Mantieni | Vendi | scenario_deterioration |
| 2026-05-08 15:10 | — | Mantieni | Weak fundamentals and high risk limit upside potential. |
| 2026-05-07 02:56 | Vendi | Mantieni | Компания показывает положительную динамику выручки, но отрицательный EPS и высокая волатильность цен указывают на значительные риски. Рекомендуется удерживать акции до получения более ясных сигналов о восстановлении. |
Previsioni analisti
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-08 13:36 | Wedbush | Target abbassato | 27 → 26 | 26.1749 |
| 2026-05-08 11:14 | Guggenheim | Target abbassato | 52 → 43 | 26.13 |
| 2026-04-29 09:43 | Barclays | Target abbassato | 44 → 43 | 24.53 |
Ancora nulla